Scientists search for blood clues in Muscle-Weakening disease treatment

NCT ID NCT07337395

First seen Jan 15, 2026 · Last updated Apr 11, 2026 · Updated 14 times

Summary

This study aims to understand how the drug ravulizumab affects people with generalized myasthenia gravis, a condition that causes muscle weakness. Researchers will analyze blood samples from 24 adult patients before and during treatment to look for changes in proteins that might indicate how well the treatment is working. The goal is to find biological markers that could help doctors monitor treatment response and understand the body's repair processes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS GENERALISED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Roma, 00168, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.